Vyanka Redenbaugh, James P Fryer, Laura Cacciaguerra, John J Chen, Tammy M Greenwood, Michael Gilligan, Smathorn Thakolwiboon, Masoud Majed, Nicholas H Chia, Andrew McKeon, John R Mills, A Sebastian Lopez Chiriboga, Jan-Mendelt Tillema, Binxia Yang, Yahya Abdulrahman, Kai Guo, Nisa Vorasoot, Cristina Valencia Sanchez, Deena A Tajfirouz, Michel Toledano, Anastasia Zekeridou, Divyanshu Dubey, Grace Y Gombolay, César Caparó-Zamalloa, Ilya Kister, Sean J Pittock, Eoin P Flanagan
OBJECTIVE: The aim of this study was to assess the diagnostic utility of cerebrospinal fluid (CSF) myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) testing. METHODS: We retrospectively identified patients for CSF MOG-IgG testing from January 1, 1996, to May 1, 2023, at Mayo Clinic and other medical centers that sent CSF MOG-IgG for testing including: controls, 282; serum MOG-IgG positive MOG antibody-associated disease (MOGAD), 74; serum MOG-IgG negative high-risk phenotypes, 73; serum false positive MOG-IgG with alternative diagnoses, 18...
April 9, 2024: Annals of Neurology